Becton, Dickinson and Company (BDX)

Earnings Preview | Q3 FY2026 | Prepared: August 5, 2026 | Upcoming Earnings Date: ~August 2026 (Q3 FY2026, fiscal quarter ended June 30, 2026)

Sector: Medical Technology | Last Earnings: May 7, 2026 (Q2 FY2026) | Sector ETF Used: IHI (iShares U.S. Medical Devices ETF)

1. Earnings Preview

Key Takeaway: The setup into Q3 FY2026 is modestly constructive — consensus is a manageable bar after two consecutive beats, the Alaris competitive tailwind is at peak intensity, and the Chloraprep ship hold resolution is the single biggest swing factor for the print.

Heading into Q3 FY2026, BDX faces a consensus revenue estimate of ~$4.89B (organic growth ~2.6%) and adjusted EPS of ~$3.14, both representing a low-to-moderate bar given the company's track record of beating on all three key metrics in Q2. Management's tone has remained deliberately prudent — explicitly flagging a 'dynamic macro environment' and declining to build in macro improvements — yet the underlying business momentum is strong: over 90% of the portfolio is growing at mid-single digits, Alaris is gaining ~150 bps of share year-to-date with the largest competitive funnel in company history entering Q3, and the BioPharma/GLP-1 segment continues to win new long-term programs. Estimate revisions have been essentially flat since the Q2 print (consensus EPS for Q3 moved from $3.144 to $3.142, revenue from $4.883B to $4.890B), suggesting the street has largely digested the Q2 beat and raised FY guidance without building in incremental upside — a modest cushion. The stock has rallied ~11% since the May 7 earnings date (from $153.26 to ~$170.66 as of August 5), outperforming IHI and the S&P 500 on an indexed basis, suggesting some beat expectation is already priced in but the multiple remains compressed relative to peers. The wildcard is the Chloraprep/PurePrep ship hold: if the ~3-week additional release testing has cleared and shipments have resumed, the Q3 revenue impact may be minimal; if the hold extended into the quarter, it could shave ~$50–75M from reported revenue and pressure the surgical segment margin.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a low-to-moderate bar on both revenue and EPS after two consecutive beats; adjusted EPS ($3.14 consensus) is the bigger swing factor given tariff headwind uncertainty and the cost-out program timing, while organic revenue growth (~2.6%) is well within the range management has guided.

Table 1 — Current Quarter Snapshot (Q3 FY2026, fiscal quarter ending June 30, 2026)

Source: Visible Alpha Consensus and Actuals Data. All consensus figures are latest available as of August 5, 2026. Q3 FY25 actuals used as prior year period. FY26 guidance midpoint of $14.90 per management's raised guidance on May 7, 2026 earnings call.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs: Total Revenue & Adj. EPS)

Note: Q1–Q4 FY25 and Q1 FY26 consensus figures reflect pre-Waters-separation estimates that included Life Sciences segment revenue; the large apparent misses are structural (segment deconsolidation), not operational. On a like-for-like New BD basis, Q2 FY26 was a clean beat on all three key metrics. Source: Visible Alpha Consensus and Actuals Data.

Pattern: Excluding the Waters separation distortion, BDX has beaten on adjusted EPS in 3 of the last 4 comparable quarters, with the most recent Q2 FY26 beat of +4.5% on EPS being the cleanest signal of the new post-separation baseline.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been essentially flat since the Q2 FY26 print — Q3 FY26 revenue consensus moved only +$7M and EPS moved -$0.002 since the post-earnings baseline — suggesting the street has absorbed the Q2 beat and raised FY guidance without building in incremental upside; the gap between consensus and guidance is narrow, leaving limited cushion but also a low bar to clear.

Source: Visible Alpha Consensus and Actuals Data. Post-earnings baseline uses consensus as of May 14, 2026 (5 trading days after May 7, 2026 earnings). Current consensus as of August 5, 2026. FY26 EPS consensus reflects sum of quarterly actuals + remaining quarter estimates; FY guidance of $14.75–$15.05 is management’s full-year adjusted EPS range.

Commentary: The near-zero revision delta since the Q2 print is notable — it suggests the street has fully priced in the Q2 beat and raised guidance without adding incremental optimism. This creates a low bar for Q3 but also means any upside surprise would need to come from operational outperformance (Alaris share gains, Chloraprep resolution, BioPharma strength) rather than estimate drift.

5. Stock Performance

Key Takeaway: BDX has rallied ~+11.4% since the Q2 FY26 earnings date (May 7, 2026 close: $153.26 → August 5, 2026: $170.66), outperforming both IHI (+7.4%) and the S&P 500 (+5.2%) on an indexed basis; the re-rating appears driven by sentiment recovery and the Waters separation value unlock rather than estimate revisions, which have been essentially flat.

BDX vs. IHI (iShares U.S. Medical Devices ETF) vs. S&P 500 (SPY) — Indexed to 100 at May 7, 2026 (Q2 FY26 Earnings). Source: Stock Price Data.

Key events marked: (1) May 7, 2026 — Q2 FY26 earnings beat + FDA warning letter for El Paso Chloraprep/PurePrep facility announced; stock opened modestly higher but sold off intraday on the ship hold news, closing at $153.26. (2) May 12, 2026 — BD priced €600M notes due 2033 for refinancing (8-K filed). (3) July 22, 2026 — Michael Garrison retirement announced; BioPharma Systems to report directly to CEO Tom Polen. The stock has recovered steadily from its post-earnings trough of ~$140.71 (June 22) to ~$170.66 by August 5, a +21% recovery from the trough, suggesting the market has largely looked through the Chloraprep ship hold and is pricing in a clean Q3 print.

6. Material News & Developments

Key Takeaway: The most important development since Q2 earnings is the Chloraprep/PurePrep FDA warning letter and voluntary ship hold — its resolution (or lack thereof) is the single biggest swing factor for Q3 revenue; the Garrison retirement and BioPharma reporting change are secondary but worth monitoring for segment strategy continuity.

• May 7, 2026 — FDA Warning Letter & Chloraprep Ship Hold (New Negative Surprise): FDA issued a warning letter for BD’s El Paso, Texas facility (CareFusion 213, LLC) manufacturing Chloraprep and PurePrep infection prevention products, citing CGMP violations (inadequate complaint investigations, laboratory controls, contamination control). BD voluntarily placed U.S. shipments on hold pending ~3 weeks of additional final release testing. Chloraprep represents ~3.5% of U.S. BD revenue and is used in ~95% of all U.S. surgeries. Manufacturing continues uninterrupted; no patient safety signals reported; distributor channel inventory expected to cover hospitals during the hold.
• Implication: If the hold extended into Q3 FY26 (April–June 2026), it could shave $50–75M from reported revenue and pressure surgical segment margins. Resolution status is the key Q3 swing factor.
• May 7, 2026 — Vitor Roque Named Permanent CFO: Following a comprehensive external search, BD confirmed Vitor Roque (interim CFO since December 2025) as permanent CFO. Roque articulated three capital allocation priorities: share buybacks (given perceived undervaluation), tuck-in acquisitions, and balance sheet deleveraging to ~2.5x leverage.
• Implication: Removes leadership uncertainty; Roque’s 20+ years of BD operational experience and explicit buyback commitment are positives for capital return narrative.
• May 7, 2026 — Q2 FY26 Beat & FY26 EPS Guidance Raised: BDX beat on revenue, adjusted gross margin, and adjusted EPS in Q2. Full-year adjusted EPS guidance raised to $14.75–$15.05 (midpoint ~$14.90), reflecting better tariff outlook ($185M vs. prior $275M estimate) and strong first-half execution.
• Implication: Sets a higher but still achievable bar for H2; back-half margin step-up from cost-out program and tariff comparison favorability are key bridges.
• May 12, 2026 — BD Prices €600M Notes Due 2033 (Refinancing): BD’s subsidiary priced €600M of notes due 2033 for refinancing purposes (8-K filed).
• Implication: Routine balance sheet management; extends debt maturity profile consistent with CFO’s deleveraging priority.
• July 22, 2026 — Michael Garrison to Retire; BioPharma Systems Reports Directly to CEO: Dr. Michael Garrison (EVP & President, Medical Essentials and BioPharma Systems) announced retirement effective October 2, 2026, after 20+ years at BD. BioPharma Systems will now report directly to CEO Tom Polen, ‘streamlining the operating model and reflecting the segment’s strategic importance as a growth driver.’ A comprehensive search is underway for the next Medical Essentials president.
• Implication: BioPharma Systems reporting directly to the CEO signals elevated strategic priority for the GLP-1/biologics growth engine. Medical Essentials leadership transition is a near-term watch item but Garrison remains through fiscal year-end.
• Ongoing — Alaris Competitive Tailwind at Peak Intensity: ICU Medical’s Novum IQ LVP remains under ship hold/installation hold, creating a pure offensive environment for BD’s Alaris sales force. BD entered Q3 FY26 with the largest Alaris competitive funnel in company history and ~150 bps of share gains year-to-date.
• Implication: Q3 FY26 is the peak window for Alaris competitive conversions; any acceleration in signed deals or installations would be a positive read-through for MMS segment revenue.
• Ongoing — PowerPort Litigation (First Bellwether Trial): First bellwether trial concluded with a partial defense verdict — BD/Bard prevailed on failure-to-warn, failure-to-instruct, and consumer fraud claims, but the jury was hung on the core design defect theory (retrial scheduled). Additional bellwether trials scheduled through end of 2026 and into early 2027.
• Implication: Partial win reduces tail risk but design defect retrial keeps litigation overhang alive; not expected to be a Q3 earnings driver but remains a long-term watch item.

7. Peer Commentaries — Read-Through for Q3 FY2026 (Last 60 Days)

Key Takeaway: Peer commentary from the last 60 days is broadly constructive for BDX’s Q3 FY2026 print — hospital procedure volumes are steady, capital spending is stable, and the infusion pump competitive landscape remains favorable for BD; the most important read-throughs are from Baxter (hospital demand + infusion), ICU Medical (pump market dynamics), and West Pharmaceutical (GLP-1/biologics strength).

Note on scope: Only commentary from peers reporting on or after May 7, 2026 (BDX’s last earnings date) is included, and only commentary relevant to BDX’s current reporting quarter (Q3 FY2026, calendar April–June 2026) or forward-looking commentary about the current environment. Prior-quarter results commentary from before May 7, 2026 is excluded.

Baxter International (BAX) — Q2 2026 Earnings (Reported July 30, 2026)

Relevance to BDX: High — BAX competes directly in infusion systems, IV solutions, and hospital care/connectivity; its commentary on hospital demand, capital spending, and infusion pump dynamics is a direct read-through for BDX’s Medical Management Solutions (MMS) and Connected Care segments.

• Hospital demand steady; no change in capital spending: “Overall, we saw steady demand across our end markets during the quarter… To date, in the US, we have not observed any change in hospital capital spending, and our order book continues to reflect solid demand.”
• BDX Read-Through: Positive for BDX’s Alaris capital installations and Pyxis Pro placements in Q3 FY26. Stable hospital capex environment supports BD’s record Alaris competitive funnel converting to signed deals.
• Infusion systems headwind from Novum IQ ship hold continues: BAX reported that “results in the quarter reflect the net impact of lower sales due to the ongoing shipment and installation hold of the Novum IQ, LVP, customer returns, and transitions to Spectrum.” Demand for Spectrum IQ remains steady; BAX is in early stages of verification testing for corrections.
• BDX Read-Through: Strongly positive for BDX Alaris. BAX’s Novum IQ hold is still active as of Q2 2026 (calendar April–June), confirming the competitive window for BD’s Alaris sales force remains wide open entering Q3 FY26. BD’s ‘largest competitive funnel in company history’ is being validated by BAX’s continued regulatory difficulties.
• Drug compounding strong; IV solutions mixed: BAX’s drug compounding services grew double digits; IV solutions reflected “growth from a new lower baseline of demand following clinical practice changes.”
• BDX Read-Through: Neutral to slightly positive for BDX’s medication delivery solutions segment; hospital drug delivery demand is healthy.
• Tariff refund of $75M was a Q2 tailwind for BAX: BAX received a $75M tariff refund not assumed in prior guidance, contributing ~$0.11/share. For H2 2026, BAX continues to expect ~$40M of tariff impact net of mitigating actions.
• BDX Read-Through: Positive signal — if IIPA tariff refunds are flowing to peers, BDX may also benefit. BDX’s tariff headwind for FY26 is already guided at $185M (improved from $275M); any refund would be incremental upside.
• BAX raised full-year organic sales growth guidance: “We are raising our outlook for full year organic sales growth to reflect the strong Q2 performance and our confidence in the back half of the year.” Q2 global sales of ~$3B grew 5% on both a reported and organic basis, ahead of expectations.
• BDX Read-Through: Broadly positive for medtech sector demand; BAX’s beat-and-raise in a quarter where BDX is also reporting suggests the hospital end market was healthy in calendar Q2 2026.

ICU Medical (ICUI) — Q1 2026 Earnings (Reported May 7, 2026)

Relevance to BDX: Very High — ICUI is BDX’s most direct competitor in infusion pumps (Alaris vs. Novum IQ/Spectrum). ICUI’s commentary on the pump market, competitive dynamics, and regulatory environment is the most direct read-through for BDX’s Alaris business.

• Record pump quarter; IV Systems grew 8% reported / 6% organic: ICUI reported “it was again a record quarter in pumps” with IV Systems growing 8% reported and 6% organic in Q1 2026. For Q2 and near term, ICUI expected organic growth to “continue at this rate or above.”
• BDX Read-Through: Mixed — ICUI’s own pump business is growing, but its Novum IQ LVP remains under ship hold. The competitive funnel for BD is driven by Novum IQ’s regulatory difficulties, not ICUI’s Spectrum (which is performing well). BD’s share gains are coming from customers who cannot get Novum IQ.
• Capital environment is ‘status quo’; investments getting done: “The capital environment is status quo, and it does appear investments that customers need to get done are getting done.”
• BDX Read-Through: Positive for BDX Alaris capital installations; stable capex environment supports BD’s record competitive funnel converting.
• FDA elevating testing requirements for new infusion pump submissions: ICUI noted the FDA is “continuing to raise the bar to ensure improved safety in the infusion pump landscape,” requiring larger sample sizes for new Medfusion and CADD hardware submissions. ICUI’s new hardware clearances will take “a little bit more time.”
• BDX Read-Through: Positive for BDX — higher FDA bar for new pump submissions extends the competitive moat for BD’s already-cleared Alaris platform and delays any new competitive entrants.
• Replacement cycle for ICUI’s own installed base is ‘more of a 2027 opportunity’: ICUI noted its own pump replacement cycle is a 2027 opportunity, with conversations starting now and real energy expected towards end of 2026.
• BDX Read-Through: Positive for BDX — ICUI’s installed base replacement cycle starting in 2027 means BD has a clear runway through FY26 and into FY27 to capture competitive conversions before ICUI’s own customers begin upgrading.

West Pharmaceutical Services (WST) — Q2 2026 Earnings (Reported July 23, 2026)

Relevance to BDX: High — WST is a key supplier of drug containment and delivery components for biologics and GLP-1 injectables. Its commentary on biologics demand, GLP-1 growth, and pharma customer behavior is a direct read-through for BDX’s BioPharma Systems segment (biologics/GLP-1 drug delivery).

• Biologics Market Group up 29% organically in Q2 2026: WST’s Biologics Market Group grew 29% organically, driven by NovaPure and FluroTec. “Approximately 75% of new drug approvals in 2025 are large drug molecules, up significantly from prior years.” WST maintains >90% win rates for new biologic molecules.
• BDX Read-Through: Strongly positive for BDX’s BioPharma Systems segment. WST’s biologics strength confirms the structural tailwind for injectable drug delivery components. BDX’s biologics business is now ~55% of BioPharma Systems revenue and growing mid-to-high single digits.
• GLP-1 components grew high teens in Q2; full-year guidance raised to 10–11% organic: WST’s GLP-1 HPE components grew high teens in Q2, “slightly better than expected.” Full-year organic growth guidance raised to 10–11% (from 7–9%). “The global adoption of GLP-1 therapies is still in its early stages.” Generic GLP-1 launches in ex-U.S. markets are contributing now and expected to be ‘even bigger contributors’ in 2027.
• BDX Read-Through: Positive for BDX’s GLP-1 drug delivery business. BDX announced two new significant long-term GLP-1 program wins in Q2 FY26 and has signed over 80 GLP-1 biosimilar deals. WST’s high-teens GLP-1 growth validates the demand environment BDX is selling into.
• Asia Pacific led with 27% organic growth; China is the largest growth driver within APAC: “The largest growth from a geographic point of view is China, followed by India and then South Korea.” Growth is driven by GLP-1 biosimilars and innovative biologics.
• BDX Read-Through: Nuanced — WST’s China strength is in biologics/GLP-1 drug delivery components (a different market than BDX’s China VBP-impacted medical devices). BDX’s China headwind is in medical essentials/devices, not pharma systems. WST’s data does not change BDX’s China VBP trajectory.
• Oral GLP-1 viewed as incremental, not a threat to injectable demand: WST noted “injectables continue to show meaningful efficacy advantages and a substantial reduction in adverse events when compared to oral alternatives” and anticipates “continued growth in both oral and injectable GLP-1 formats.”
• BDX Read-Through: Positive — aligns with BDX management’s view that oral GLP-1 is incremental and complementary, not a threat to injectable demand. Reduces a key bear case risk for BDX’s GLP-1 drug delivery business.

Intuitive Surgical (ISRG) — Q2 2026 Earnings (Reported July 16, 2026)

Relevance to BDX: Moderate — ISRG’s commentary on hospital procedure volumes, U.S. capital spending, and China dynamics provides a broad medtech sector read-through. ISRG also competes in surgical procedures where BDX’s Surgery segment (GalaFLEX, TFA) participates.

• U.S. procedure growth moderated; ACA premium expiration cited as modest headwind: U.S. Da Vinci procedure growth was 12% in Q2 2026, moderating from recent trends. ISRG cited “changes in patient coverage and premium dynamics” (ACA enhanced premium subsidy expiration) as a “modest adverse impact.” Benign procedures saw slight moderation.
• BDX Read-Through: Mild negative watch item — if ACA premium changes are reducing elective procedure volumes, it could modestly affect BDX’s surgical segment (Chloraprep, GalaFLEX). However, BDX’s surgical exposure is primarily to essential/non-elective procedures, limiting the impact.
• U.S. capital environment stable; ~70% of systems under leasing: “The US capital environment, at least in our experience, has been stable for some time now.” ~70% of ISRG systems acquired under leasing arrangements, providing flexibility for capital-constrained customers.
• BDX Read-Through: Positive for BDX’s capital equipment businesses (Alaris, Pyxis Pro, APM); stable U.S. hospital capex environment supports BD’s record competitive funnel.
• China remains challenging; only 2 systems placed in Q2: “In China, the environment remains challenging. We continue to see lower tender activity, increased domestic robotic competition and policy-driven pricing pressure.” Only 2 Da Vinci systems placed in China in Q2 2026.
• BDX Read-Through: Consistent with BDX’s own China narrative (mid-teens revenue decline, VBP pressure). No new information; confirms China headwinds are sector-wide and not BDX-specific.
• GLP-1 impact on bariatric surgery: ISRG noted “U.S. Da Vinci bariatric cases continued to feel the impact of rising GLP-1 usage, declining high single digits during the quarter.”
• BDX Read-Through: Positive for BDX’s Surgery segment — BDX management has highlighted GLP-1 surgery as a tailwind for skin and tissue lift procedures (GalaFLEX), as GLP-1 patients often require reconstructive surgery. ISRG’s data confirms GLP-1 is reshaping surgical procedure mix in ways that benefit BDX.

Cooper Companies (COO) — Q2 FY2026 Earnings (Reported June 4, 2026)

Relevance to BDX: Low-to-Moderate — COO’s commentary on Asia Pacific softness, pricing dynamics, and medtech market conditions provides a broad sector read-through, though COO’s business (contact lenses, fertility) has limited direct overlap with BDX.

• Asia Pacific soft; China and Japan weaker than expected: “Asia Pac was mixed with softness in China, offset by strength in other markets.” COO expects Asia Pac to decline in Q3 due to market pressure and ongoing portfolio rationalization.
• BDX Read-Through: Consistent with BDX’s China narrative; confirms Asia Pacific softness is broad-based and not BDX-specific. No new information for BDX’s China VBP trajectory.
• Pricing ‘okay’ in U.S. and EMEA; no pushback on price increases: “Price is okay when it comes to the U.S. market. Okay in EMEA, it’s still a challenge in Asia Pac.” Outside Asia Pac, “continued interest in premium products, higher-priced products, and there’s not a pushback necessarily on some of the price increases.”
• BDX Read-Through: Positive for BDX’s pricing power in U.S. and international markets outside Asia. BDX’s CPI-linked contract clauses and annual price increase reviews should face limited pushback in the current environment.
• Record revenue; 10th consecutive quarter of beating consensus: COO delivered record revenue and non-GAAP EPS in Q2, marking its 10th consecutive quarter of beating consensus.
• BDX Read-Through: Broadly positive sector signal — medtech companies with strong execution are continuing to beat consensus, suggesting the bar is manageable for BDX.

8. Insider Transaction Activity

Key Takeaway: No open-market buys from insiders since the Q2 earnings date; all sales are 10b5-1 planned sales (pre-scheduled, not discretionary), and the CEO’s June 1 disposition was also plan-driven — no meaningful insider signal either way; the absence of discretionary buying at depressed post-earnings prices ($140–$150 range in May–June) is a mild negative but not alarming given the 10b5-1 context.

Source: Insider Transaction Data (SEC Form 4 filings). Open-market buys (code P) and open-market sells (code S) only for discretionary signal; awards (code A), tax withholding (code F), and deferred compensation rights are non-discretionary and excluded from signal analysis.

Summary: Zero open-market buys since the Q2 FY26 earnings date. All sales are 10b5-1 pre-scheduled plans (CEO Polen, CRO Feld, Garrison) — these are obligation-driven and carry no negative signal. The CEO’s 17,445-share disposition on June 1 (when the stock was trading ~$145) is the largest transaction by size but is plan-driven. Garrison’s continued 10b5-1 sales in June are consistent with his pre-announced retirement. No insider has made a discretionary open-market purchase at the post-earnings depressed prices ($140–$150 range), which is a mild negative but not unusual for a company with active 10b5-1 programs. Overall:

No meaningful insider signal — neither a bullish buy cluster nor an alarming discretionary sell pattern.